Evidence map›Paper›PMID 36436128›Full record

Trial reportBreast cancer research and treatment2023

Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.

Shoshana M Rosenberg, Yue Zheng, Shari Gelber, Kathryn J Ruddy, Philip Poorvu, Tal Sella, Rulla M Tamimi, Johanna Wassermann, Lidia Schapira, Virginia F Borges and 4 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01468246 (Helping Ourselves, Helping Others), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01468246 active not recruitingnot on this map

Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study

TypeobservationalSponsorDana-Farber Cancer InstituteRan2006 to 2035Enrolled1,302ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Impact of motivational interviewing on psychosocial and symptom outcomes during breast cancer endocrine therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Shoshana M RosenbergDepartment of Population Health Sciences, Weill Cornell Medicine, 402 E 67St LA-0005, New York, NY, 10065, USA. shr4009@med.cornell.edu.ORCID http://orcid.org/0000-0002-0074-6385
Yue ZhengData Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Shari GelberMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kathryn J RuddyMedical Oncology, Mayo Clinic, Rochester, MN, USA.
Philip PoorvuMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tal SellaMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, 402 E 67St LA-0005, New York, NY, 10065, USA.
Johanna WassermannBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Lidia SchapiraDepartment of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA.
Virginia F BorgesMedical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Steven ComeHarvard Medical School, Boston, MA, USA.
Jeffrey PeppercornHarvard Medical School, Boston, MA, USA.
Karen R SepuchaHarvard Medical School, Boston, MA, USA.
Ann H PartridgeMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard University · USDana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USCornell University · USMayo Clinic in Arizona · USSorbonne Université · FRStanford University · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Improving surgical decision-making in young women with breast cancerK01HS023680 · AHRQ · DANA-FARBER CANCER INST · PI ROSENBERG, SHOSHANA M · 2015 to 2019
$594k
AHRQ HHS K01 HS023680NCI NIH HHS L30 CA179751
6 · The paper itself

Abstract

purposeCharacterizing oral adjuvant endocrine therapy (ET) non-initiation and non-persistence in young women with breast cancer can inform strategies to improve overall adherence in this population.

methodsWe identified 693 women with hormone receptor-positive, stage I-III breast cancer enrolled in a cohort of women diagnosed with breast cancer at age ≤ 40 years. Women were classified as non-initiators if they did not report taking ET in the 18 months after diagnosis. Women who initiated but did not report taking ET subsequently (through 5-year post-diagnosis) were categorized as non-persistent. We assessed ET decision-making and used logistic regression to identify factors associated with non-initiation/non-persistence and to evaluate the association between non-persistence and recurrence.

resultsBy 18 months, 9% had not initiated ET. Black women had higher odds and women with a college degree had lower odds of non-initiation. Among 607 women who initiated, 20% were non-persistent. Younger age, being married/partnered, and reporting more weight problems were associated with higher odds of non-persistence; receipt of chemotherapy and greater hot flash and vaginal symptom burden were associated with lower odds of non-persistence. Adjusting for age and clinical characteristics, non-persistence was associated with lower odds of recurrence. Women who initiated were more likely to report shared decision-making than non-initiators (57% vs. 38%, p = 0.049), while women who were non-persistent were less likely to indicate high confidence with the decision than women who were persistent (40% vs. 63%, p < 0.001).

conclusionInterventions to improve ET decision-making may facilitate initiation and address barriers to adherence in young breast cancer survivors.

trial registrationwww. CLINICALTRIALS: gov , NCT01468246.

Indexed as

Breast NeoplasmsCancer SurvivorsAdjuvants, ImmunologicAdultAntineoplastic Agents, HormonalChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansAdjuvants, ImmunologicAntineoplastic Agents, HormonalAdherenceAdjuvant endocrine therapyBreast cancerNon-initiationSurvivors

Identifiers

PMID36436128
PMCPMC10233447
OpenAlexW4310276768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.